Drug Topics August 18, 2024
Perhaps unsurprisingly, GLP-1 therapies are expected to continue making headlines within the industry.
Each year, attendees at the National Association of Chain Drug Stores Total Store Expo look forward one particular presentation: IQVIA’s overview of pharmacy trends, issues, and forecasts for the current and upcoming year.
This year, Drug Topics was joined by Scott Long, director of supplier services at IQVIA, and Doug Long, vice president of industry relations at IQVIA, ahead of their August 19 presentation.
Perhaps as expected, glucagon-like peptide-1 (GLP-1) medications—a category that includes blockbuster therapies semaglutide and tirzepatide (Ozempic and Wegovy, and Mounjaro and Zepbound, respectively)—is one of the biggest areas that pharmacy forecasters are keeping a weathered eye on. “It’s a very large...
Today's Sponsors
Today's Sponsor